Physician profile
Andrew G Meador
NPI 1134462450
$93,513.08
in general payments reported to CMS, 2019-2025
9 companies · $8,890 in 2025
The $8,890 reported for 2025 was more than what 90% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.78 · 2020: $10K · 2021: $9,417 · 2022: $22K · 2023: $23K · 2024: $21K · 2025: $8,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $13K · Travel and Lodging: $3,238 · Food and Beverage: $2,072 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $20,350.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,650.00 |
| Consulting Fee | $13,125.00 |
| Travel and Lodging | $3,237.68 |
| Food and Beverage | $2,071.70 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $63,857.32 | 2020-2023 | Tepezza |
| Amgen INC. | $29,385.30 | 2024-2025 | Tepezza |
| Genentech USA, INC. | $141.44 | 2021-2024 | Erivedge |
| Johnson & Johnson Vision Care, INC. | $44.93 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $19.01 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.85 | 2019 | |
| Genentech, INC. | $15.45 | 2023 | Erivedge |
| Galderma Laboratories, L.P. | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Meador listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.